Authors
Latest:
Dr. Tasian on the Heterogeneity of Ph-Like ALL in Pediatric PatientsSarah K. Tasian, MD, an attending physician and assistant professor of pediatrics in the Division of Oncology at Children’s Hospital of Philadelphia, discusses the heterogeneity of pediatric Philadelphia (Ph)-like acute lymphoblastic leukemia.
Latest:
Best Practices With CAR T-Cell Therapy Being Refined in LymphomasAlison R. Sehgal, MD, discusses the latest developments with CAR T-cell therapy in lymphomas.
Latest:
Treatment Advances in HR+/HER2- MBCFinal takeaways from a discussion on best practices treating HR+/HER2- metastatic breast cancer with CDK4/6 inhibitors and PI3K therapies based on data presented at ESMO 2021.
Latest:
Neoadjuvant Radiosurgery Shows Efficacy for Large Brain MetastasesNeoadjuvant stereotactic radiosurgery has gained interest. This approach allows for easier target delineation; a smaller margin of normal brain parenchymal receiving the radiosurgery dose, which may decrease toxicity; and the potential to reduce the risk of leptomeningeal disease by sterilizing the tumor margin preoperatively.
Latest:
Dr. Larson on the Impact of MRD on Treatment Decisions in Multiple MyelomaSarah M. Larson, MD, assistant professor of medicine, and director, Multiple Myeloma Program, University of California, Los Angeles, discusses the impact of minimal residual disease (MRD) on treatment decisions in multiple myeloma.
Latest:
Colorectal Cancer: A ReviewColorectal cancer is the third most common type of cancer diagnosed in the United States and is the third most common cause of cancer-related death.
Latest:
Lunning and Rutherford Detail Considerations for BV-AVD Use in Older Patients With Hodgkin LymphomaDrs Lunning and Rutherford discuss findings from the ECHELON-1 trial of BV-AVD in the cohort of patients with Hodgkin lymphoma over 60 years of age.
Latest:
Oncology Surgeons Need Better Training in Palliative CareIt is important for oncology surgeon trainees to learn to recognize when a palliative surgical procedure for an advanced malignancy might be appropriate, be familiar with the conduct of these operations, and understand the nuances of postoperative care and management of complications in this unique patient population.
Latest:
Dr. Chandarlapaty on Responses to Amcenestrant/Palbociclib in ER+/HER2- Metastatic Breast CancerSarat Chandarlapaty, MD, PhD, highlights responses to amcenestrant and palbociclib in patients with estrogen receptor–positive, HER2-negative metastatic breast cancer, as seen in the phase 1/2 AMEERA 1 trial.
Latest:
Dr Neelapu on Clinical Trial Data With CAR T-Cell Therapy in LymphomaSattva S. Neelapu, MD, discusses key clinical trial data that support the use of CAR T-cell therapy in standard practice for patients with lymphoma.
Latest:
Dr Neelapu on Streamlining the Delivery of CAR T-Cell Therapy in LymphomaSattva S. Neelapu, MD, discusses processes that have been adopted to streamline the delivery of CAR T-cell therapy to patients with lymphoma.
Latest:
Oncologists Must Help Patients Overcome Fear of Genetic Testing to Uncover Cancer RisksIn the current digital age, where all-too-personal information flows from Facebook and Twitter, it seems that the health information available through the process of genetic testing would be an idea welcomed by most of the public.
Latest:
Dr. Chhabra on Impactful Advances in Relapsed/Refractory Multiple MyelomaSaurabh Chhabra, MD, MS, assistant professor at the Medical College of Wisconsin, discusses the most impactful advances made in relapsed/refractory multiple myeloma.
Latest:
Higher Incidence, New Therapies Add to Cost of Treating Advanced Pancreatic CancerPancreatic cancer is one of the few cancers that is on the rise, and this means that the overall cost of treating this disease is also climbing.
Latest:
Evolving Strategies Using Hematopoietic Stem Cell Transplantation in Diffuse Large B-Cell Non-Hodgkin LymphomaDiffuse large B-cell non-Hodgkin lymphoma is typically a chemotherapy-sensitive malignancy, justifying dose-intense therapy with hematopoietic stem cell transplantation for patients unlikely to achieve cure with standard-dose regimens.
Latest:
Dr. Eggener on PSA-Based Screening in Early-Stage Prostate CancerScott Eggener, MD, associate professor of Surgery, Urologic Oncology, at the University of Chicago Medicine, discusses his views on PSA-based screening and how to appropriately use it for patients with early-stage prostate cancer. Eggier shared these thoughts during the 2016 OncLive State of the Science Summit on GU and Prostate Cancer.
Latest:
Dr. Gettinger on Lung Cancer ImmunotherapiesScott Gettinger, MD, associate professor of medicine (medical oncology), Yale School of Medicine, explains the development of immunotherapies in lung cancer.
Latest:
Dr. Glaser on Managing Radiation-Induced AEs in Early Breast CancerScott Glaser, MD, assistant clinical professor of radiation oncology, City of Hope, discusses strategies for managing radiation-induced adverse events in patients with early-stage breast cancer.
Latest:
The Use of Tyrosine Kinase Inhibitors for Gastrointestinal Stromal Tumors (GIST)In this review article, the author discusses the use of tyrosine kinase inhibitors in the management of patients with gastrointestinal stromal tumors.
Latest:
Dr. Antonia on Investigational Immunotherapy Combinations in Stage III NSCLCScott J. Antonia, MD, PhD, instructor, Duke University School of Medicine, member, Duke Cancer Institute, discusses investigational immunotherapy combinations in stage III non–small cell lung cancer (NSCLC).
Latest:
Dr. Swanson on Treating Multifocal Lung CancerScott J. Swanson, MD, co-director of Minimally Invasive Surgery and chief surgical officer at Brigham and Women’s Hospital, professor of Surgery at Harvard Medical School, discusses treating multifocal lung cancer.
Latest:
Dr. Swanson on Surgical Choices for Multifocal Lung CancerScott J. Swanson, MD, co-director of Minimally Invasive Surgery and chief surgical officer at Brigham and Women’s Hospital, professor of Surgery at Harvard Medical School, discusses surgical choices for patients with multifocal lung cancer.
Latest:
Dr Kopetz on the Future Utility of Adagrasib/Cetuximab in KRAS G12C–Mutant CRCScott Kopetz, MD, PhD, FACP, discusses the potential FDA approval of adagrasib in combination with cetuximab in KRAS G12C-mutatated colorectal cancer.
